AMC Research is recruiting patients near Charlotte, North Carolina, for a clinical trial of a promising new experimental treatment for Alzheimer’s disease | national company

MATTHEWS, NC–(BUSINESS WIRE)–Sept. 7, 2022–

AMC Research launches clinical trial for promising new experimental treatment for Alzheimer’s disease (AD) in Matthews, NC

This press release is multimedia. See the full version here: https://www.businesswire.com/news/home/20220907005335/en/

Dr. Bolouri (Photo: Business Wire)

The Phase I study will determine the safety and tolerability of a single intravenous (IV) dose and multiple IV doses of ACU193. We are asking people who have memory problems to consider joining the trial to help evaluate this drug for the treatment of Alzheimer’s disease. There is no cost to participate. Acumen Pharmaceuticals Inc.a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for AD, is sponsoring the clinical trial.

ACU193 targets beta-amyloid oligomers and is a different approach to treating Alzheimer’s disease than currently approved drugs. ACU193 is designed to locate and bind to beta-amyloid oligomers, proteins that accumulate in the brains of people with Alzheimer’s disease. These proteins are thought to be involved in the symptoms and progression of Alzheimer’s disease.

The trial site, located at 10801 Monroe Road Suite #100, Matthews, NC 28105, is led by principal investigator Dr. Mohammad Bolouri at AMC Research. Patients who believe they are eligible for the study should call (704) 364-4000 ext. 235 or email [email protected] to learn more.

“We are excited to open this trial at Matthews to study ACU193 for the treatment of Alzheimer’s disease,” said Dr. Bolouri. “If you or a loved one is having memory problems, contact us to find out more about the study. More than 6 million Americans live with Alzheimer’s disease. New safe and effective treatments are needed more than ever. Participating in clinical trials is one way for members of our community to help make a difference.

Key eligibility criteria:

  • From 55 to 90 years old.
  • You have memory problems which could be a sign of mild cognitive impairment (usually mild memory loss) or mild dementia. The underlying cause of these memory problems may or may not be due to Alzheimer’s disease. The tests given as part of the study will help determine this.
  • Have a caregiver or study partner; someone who knows the participant very well, who is willing to participate in the study and who can attend study visits with the participant.
  • The study center staff will explain the full list of requirements to you.

This study is the first time that ACU193 will be given to people. As all medications and medical procedures carry a risk of side effects, participants may experience some discomfort or other reactions from using ACU193. Study personnel will explain these potential risks before potential participants decide whether or not to participate in the study. Participants’ safety will be closely monitored throughout the study.

Study participants will receive a full diagnostic workup, including an amyloid PET scan and MRI that can provide a more accurate diagnosis and help guide future treatment options. After completing this study, participants may consider participating in future ACU193 studies in which all participants may receive ACU193 at some point during the study.

About ACU193

ACU193 is a monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble AβO, which Acumen claims is the most toxic and pathogenic form of Aβ compared to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function, and induce neurodegeneration. By selectively targeting toxic soluble AβO, ACU193 aims to directly address what a growing body of evidence points to as a primary underlying cause of the neurodegenerative process in AD.

About AMC Research

Alzheimer’s Memory Center (AMC) is Charlotte’s first center dedicated to the comprehensive management of Alzheimer’s disease and related dementias, including mild cognitive impairment (MCI), vascular dementia, frontotemporal dementia, pseudo -dementia, dementia with Lewy bodies and parkinsonian dementia. They serve residents of the Charlotte metropolitan area, as well as residents of North and South Carolina. They are conveniently located minutes from several major hospitals with easy access to several highways and an international airport. The facility includes a comprehensive research facility operated by highly qualified and well-trained personnel, with a CLIA-certified laboratory for the collection of clinical trial samples.

Show source version on businesswire.com:https://www.businesswire.com/news/home/20220907005335/en/

CONTACT: Media:

Shereen Bolouri RN, BSN Recruitment Specialist

(704) 364-4000 ext. 235

[email protected]

KEYWORD: NORTH CAROLINA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH MENTAL HEALTH SENIORS CLINICAL TRIALS OTHER HEALTH GENERAL HEALTH PHARMACEUTICAL CONSUMER HEALTH SCIENCE

SOURCE: CMA Research

Copyright BusinessWire 2022.

PUBLISHED: 07/09/2022 08:00/DISC: 07/09/2022 08:03

http://www.businesswire.com/news/home/20220907005335/en

Copyright BusinessWire 2022.

Elna M. Lemons